Home/Montis Biosciences/Gil Beyen

GB

Gil Beyen

CEO

Montis Biosciences

Therapeutic Areas

Neuroinflammatory Diseases Autoimmune Diseases Neurodegenerative Diseases Ophthalmic Diseases Oncology

Montis Biosciences Pipeline

Drug	Indication	Phase
Anti-C1q Antibody	Guillain-Barré Syndrome (GBS) & other neuroinflammatory diseases	Preclinical
Anti-CD93 Antibody	Lung Squamous Cell Carcinoma (LUSC)	Preclinical

Leadership Team at Montis Biosciences

VP Research & Development

Federico Grossi

Clinical Advisor & Acting CMO

Chairman of the Board

View full Montis Biosciences profile